Fuller & Thaler Asset Management
HBIO icon

Fuller & Thaler Asset Management’s Harvard Bioscience HBIO Stock Holding History

Fuller & Thaler Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-47,695
Closed -$2.24M – 692
2013
Q4 		$2.24M Sell
47,695
-11,554
-20% -$505K 0.12% 189
2013
Q3 		$2.36M Buy
59,249
+6,964
+13% +$274K 0.14% 198
2013
Q2 		$1.86M Buy
+52,285
New +$2M 0.13% 203

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCAM
F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fuller & Thaler Asset Management's HBIO Position: Q1 2014 in Review

Fuller & Thaler Asset Management sold out of Harvard Bioscience (HBIO) in Q1 2014, closing a stake of 47,695 shares — an estimated $2.24M sold.

Fuller & Thaler Asset Management first reported a position in HBIO in Q2 2013 and held it in 3 quarters. The position peaked at $2.36M in Q3 2013. 74 funds tracked by Wall St. Rank hold HBIO as of Q1 2014.

  • Fuller & Thaler Asset Management reported no remaining Harvard Bioscience position as of Q1 2014 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 47,695 Harvard Bioscience shares in Q1 2014, an estimated $2.24M.
  • Fuller & Thaler Asset Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's Harvard Bioscience position peaked at $2.36M in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2014.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2014, filed 13 May 2014.